Newton Biocapital

About Newton Biocapital

Newton Biocapital is a venture capital fund deeply rooted in the biotech and life science sectors, gearing its financial instruments towards the growth and evolution of these industries. With assets under management of around 100 million, they exhibit significant involvement in financing innovative biotech and life science projects in Europe and Japan. Founded in 2017 with a headquarters in Frankfurt am Main, Germany, Newton Biocapital operates on the prowess of equity and debt to support early-stage ventures, management buyouts/leveraged buyouts, and acquisitions. The fund operates with a specific focus towards chronic health conditions, aiming to alleviate patient and societal burdens through its investment strategy. Their specialty stretches into the spheres of chronic health issues, where identifying and nurturing promising solutions becomes their mission. In doing so, they leverage scientific and medical expertise alongside their network to pinpoint and pursue the most promising investment opportunities across Europe and Japan. Newton Biocapital is actively involved in their portfolio companies, engaging as board members and providing guidance in preclinical and clinical program selections across a variety of technologies and disease areas. The fund prides itself on its strong ties to the life sciences ecosystems in both regions, facilitating synergy and creating mutually beneficial relationships that pave the way to optimal exits for their investments. Their focus industries include Biotech, Hardware, Medical Devices, Healthcare, Life Science, Oncology, Consumer, Pharmaceutical, and Industrials. By opening doors through connections with local and international investors as well as pharma, they ensure that their portfolio companies are well-positioned to achieve significant developmental milestones and business growth.